APA (7th ed.) Citation

AA, M., SSN, P., S, G., S, A., N, J., J, C., . . . SS, B. (2025). Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes. Human antibodies, 33(1-2), 10. https://doi.org/10.1177/10932607241301699

Chicago Style (17th ed.) Citation

AA, Mandavkar, et al. "Emerging Therapies in Multiple Myeloma: Leveraging Immune Checkpoint Inhibitors for Improved Outcomes." Human Antibodies 33, no. 1-2 (2025): 10. https://doi.org/10.1177/10932607241301699.

MLA (9th ed.) Citation

AA, Mandavkar, et al. "Emerging Therapies in Multiple Myeloma: Leveraging Immune Checkpoint Inhibitors for Improved Outcomes." Human Antibodies, vol. 33, no. 1-2, 2025, p. 10, https://doi.org/10.1177/10932607241301699.